Bronchopulmonary DysplasiaREPORT-BPDNCT05235399
Right vEntricular Function Prediction mOdel to Identify pReterm infanTs With Early BronchoPulmonary Dysplasia.
An observational study of Bronchopulmonary Dysplasia and Right Ventricular Dysfunction, run by University Hospital Plymouth NHS Trust at 1 site in United Kingdom.
Trial summary
Short title REPORT-BPD feasibility study Design A mixed methods observational cohort feasibility study Study Setting Neonatal Intensive Care Unit at University Hospitals Plymouth NHS Trust Aim To explore the feasibility of measuring the right ventricular function of the premature heart to develop a prediction model to… Read more about this study
- Who is it for?
- Ages 2 to 2 days
- Conditions the study is for
- Bronchopulmonary Dysplasia, Right Ventricular Dysfunction, In the Perinatal Period
- What is being tested?
- Echo scans
- How many people
- 40 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 Jun 2022to 5 May 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 to 2 days
- All sexes
- Child
Study population: The exploratory nature of this feasibility study dictated to set a realistic target of recruiting 40 preterm infants who are born before 32 weeks of gestation.
Who may be able to join
- Born at < 32 weeks gestational age.
- The echo scans are indicated as per the recommended neonatal practice:
- Preterm infants who require mechanical ventilation or non-invasive respiratory support (CPAP ≥ 4 cm H2O, High Flow ≥ 4 L/min).
- Detection of a cardiac murmur in the first three days after birth.
- Assessment of patent ductus arteriosus (PDA).
- Preterm infants have central line in-situ, so echo is needed to assess line position.
Who cannot join
- Preterm infants with major congenital anomalies, such as pulmonary hypoplasia or congenital heart disease (except PFO or PDA).
- Preterm infants with a poor prospect of survival.
- Preterm infants whose parents do not consent.
- Preterm infants who are still in need of blood pressure supporting medications, such as, (inotropes) when the study echo scans are due.
- Preterm infants need inhaled nitric oxide gas when the study echo scans are due.
- PDA - patent ductus arteriosus, PFO - patent foramen ovale
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
University Hospital Plymouth NHS Trust (UHP)
Plymouth, Devon, PL6 5FP
About this study
Official title: Exploring Right vEntricular Function Applicability in a Prediction mOdel to Identify pReterm infanTs With Early BronchoPulmonary Dysplasia (REPORT - BPD Study): a Mixed Methods Observational Cohort Feasibility Study
Short title REPORT-BPD feasibility study
Design A mixed methods observational cohort feasibility study
Read more
Study Setting Neonatal Intensive Care Unit at University Hospitals Plymouth NHS Trust
Aim To explore the feasibility of measuring the right ventricular function of the premature heart to develop a prediction model to identify early BronchoPulmonary Dysplasia in premature infants.
Objectives 1. To assess the feasibility and acceptability of the study procedures e.g., recruitment, echo scans performance, data collection, storage, and analysis.
- To identify the sensitive echo parameters in assessing the right ventricle function of the heart to be included in a prediction model to identify early BPD in premature infants.
Study Participants Preterm infants born <32 weeks of gestational age, their parents and healthcare professionals involved in the care of the study's preterm infants.
Sample size 40 preterm infants
Follow-up Each preterm infant will be followed up till they are 36 weeks of post menstrual age (PMA) or until discharge home whichever comes first.
Study Period 18 months
Outcome Measures
- Establishing sensitive and feasible echo parameters for detecting right ventricle dysfunction associated with early BPD pulmonary vascular changes.
- Suitability of eligibility criteria and sample characteristics.
- Fidelity to the study procedures such as recruitment, data collection including echo scans performance at the set time points.
- Recruitment, accrual, and retention rates.
Read the detailed description
RATIONALE The current research findings demonstrated a persistently elevated myocardial performance index of the right ventricle (RV) in the first two weeks of postnatal life (WoPL) in preterm infants with incipient BPD. The identification of the early myocardial dysfunction of RV that is associated with early pulmonary vascular disease (PVD) through echo scan examination in the first two WoPL can potentially serve as a marker for detecting preterm infants with an early BPD.
Data from 1,735 infants born between 23-30 weeks of gestational age (GA) showed that the proportion of preterm infants born < 31 weeks needing oxygen decreases from birth to the 7th day of postnatal life (DoPL). This is followed by a steep rise in the number of infants requiring oxygen in the same cohort at the start of the second week of postnatal life (WoPL). The number of preterm infants needing extra oxygen, peaks at the 14th DoPL. These studies indicate that the pathological pulmonary changes start as early as the first 10 DoPL. Furthermore, studies have identified the end of the first week of postnatal life (WoPL) and the beginning of the second WoPL as the time point when early respiratory problems start to surface. According to the vascular theory, the pathological processes affecting the pulmonary vascular bed are already happening before the appearance of the clinical signs associated with early BPD. The proposed study (REPORT-BPD) aims to capture the early burden exerted on the RV by early BPD and its associated pulmonary vascular changes through performing functional echo examinations at two time points, 5th and 9th day of postnatal life (DoPL) and utilising the findings to construct a prediction model.
To our knowledge, no study has used functional echo examinations to assess extra load or strain imposed by early BPD on the RV on the two time points (5th \& 9th DoPL) in the first 10 DoPL.
The cardiac muscle of the preterm infant's heart has premature function. The premature heart reduced contractility is secondary to several reasons such as less myofibrils per cross-sectional area together with immature internal organisation. In addition, there is a lower number of β-adrenergic receptors and underdeveloped sympathetic nervous network. Furthermore, the underdeveloped intrinsic myocardial function following preterm birth is the result of abnormal right ventricle performance with remodelling after birth that persists in the first year of life.
Current research supports the vascular theory as the main pathophysiology of BPD i.e., the pathological process of BPD starts in the pulmonary vascular bed prior to the involvement of the parenchyma of the lungs. So, when the early BPD respiratory insufficiency starts to manifest clinically on 7th day of postnatal life, the adverse haemodynamic changes are already ongoing. In addition, the immaturity of the right ventricle (RV) will render the RV more sensitive to the extra burden imposed by the negative haemodynamic effects of early BPD causing worsening of the RV dysfunction.
In summary, the rationale of the study is outlined nicely by a quote from Niccolo Michiavelli; an Italian diplomat, philosopher and historian, who lived during the renaissance (1469 - 1527):
"In the beginning of the malady it is easy to cure but difficult to detect, but in the course of time, not having been either detected or treated in the beginning, it becomes easy to detect but difficult to cure." To the best our knowledge, this is the first study that assesses the right ventricle dysfunction through two echo scans performed at two specified time points before and after the 7th day of postnatal life when early BPD respiratory insufficiency starts to be evident. Then, the data generated will be utilised to formulate a prediction model for early BPD. In other words, since it is very difficult to diagnose early BPD, this study will utilise highly specialised technologies in analysing the echo images and the data generated will be used to formulate a prediction model to identify BPD at its early stage. Additionally, the rationale behind incorporating qualitative work is because it is important to explore the experiences of parents and clinicians in participating in REPORT-BPD study to inform the design of a larger trial by addressing any gaps identified during this study.
OBJECTIVES
- To assess the feasibility and acceptability of the study procedures e.g., recruitment, echo scans performance, data collection, storage, and analysis.
- To identify the sensitive echo parameters in assessing the right ventricle function of the heart to be included in a prediction model to identify early BPD in premature infants.
STUDY DESIGN This is a longitudinal, observational, cohort and feasibility study. STUDY SETTING This study will be conducted at the regional tertiary neonatal intensive care unit (NICU) at University Hospitals Plymouth NHS Trust (UHP), Plymouth. The total NICU capacity is 40 neonatal admissions (6 intensive care cots, 6 high dependency care cots, 10 special care cots and 18 cots in transitional care ward).
SAMPLE AND RECRUITMENT
Sample size
The exploratory nature of this feasibility study dictated to set a realistic target of recruiting 40 preterm infants who are born before 32 weeks of gestation.
The regional tertiary NICU at the UHP admitted 89, 101 and 69 preterm infants who were born before 32 PMA in the years 2018, 2019 and 2020, respectively. Based on the careful examination of the data of the admissions in 2018; two thirds of these preterm infants met the inclusion criteria of the proposed study with one third of them i.e., eligible preterm infants developed moderate - severe BPD.
Therefore, the proposed feasibility study realistic sample size is 40 preterm infants over an 18-month recruitment period.
Participants
The participant whose data will be subjected to the trial analysis - both for the primary analysis and any applicable secondary analyses are:
- Infants survived till the gestational age when the diagnosis of no BPD or BPD with its severity can be established.
- Infants who died before the set gestational age (36 weeks PMA) with severe BPD is being the main cause of death. Participant identification The identification of eligible infants for the study will be carried out by the neonatal clinical team once a preterm infant is admitted to the regional tertiary NICU at UHP, either from the delivery suite in UHP or from another neonatal unit in the region for continuity of care. The neonatal clinical team will be consisted of the clinicians who are working in the neonatal unit such as, consultant neonatologists, trainee doctors, advanced neonatal nurse practitioners, neonatal staff nurses. While the neonatal research team is consisted of the clinicians such as, consultant neonatologists, trainee doctors and advanced nurse practitioners, who are good clinical practice (GCP) trained and registered in the study delegates' log. The neonatal clinical team will inform the neonatal research team of the potential recruits to instigate the recruitment process. Screening The screening process will occur on the possible two time points:
- Timepoint 1: If possible, antenatal screening will be carried out. The obstetric or midwifery team will inform the neonatal clinical team of the admitted women with preterm labour. This will be followed by screening for eligibility by the clinical neonatal team by reviewing the medical notes. Then the clinical neonatal team will inform the neonatal research team if the unborn infant is deemed a potential recruit so the initial conversation can happen antenatally.
- Timepoint 2: If screening is not possible at timepoint 1 parents of the suitable preterm infants will be approached in the second day after the birth of their infant. A screening log will be maintained. Consent All parents will be spoken to in person by the neonatal research team, who are also part of the neonatal clinical team, in the antenatal wards, in the delivery suite antenatally or in the neonatal unit postnatally. The neonatal research team members will clearly introduce themselves and state that this conversation will be about the parents and their preterm infants' participation in REPORT-BPD study. The talk will focus on providing a clear verbal explanation of the research project and why the parents and their preterm infants are invited to participate in this study, together with giving them a patient/parent information sheet (PIS) and informed consent form. The parents will also be given contact details for the chief investigator (CI) and the neonatal research team in case they wish to seek further information about the study. Informed and written consent to enter the study will be sought from each participant, in this case participants' parents. Signed parents' informed consent forms will be obtained prior to the participation in the study. If parents are interested in participating, a neonatal consultant, a senior trainee doctor or senior advanced nurse practitioner who is a member of the neonatal research team, will be able to dedicate some of their time to obtain consent at the second day after the birth of the potential recruit. All participants will be made aware that they are free to withdraw at any time from the study without giving reasons and without prejudicing further treatment. A delegation log will be maintained to ensure that the medical practitioners registered as a study delegate who are participating in the consenting process of this study, are duly authorised, completed a Good Clinical Practice (GCP) training, experienced clinicians and competent to participate according to the ethically approved protocol, principles of GCP and Declaration of Helsinki. DATA COLLECTION As per the standards of care echo scans are performed when one or more of the following clinical indications are present:
- Preterm infants who require mechanical ventilation or non-invasive respiratory support (CPAP ≥ 4 cm H2O, High Flow ≥ 4 L/min).
- Detection of a cardiac murmur in the first three days after birth.
- Assessment of patent ductus arteriosus (PDA).
- Preterm infants have central line in-situ, so echo is needed to assess line position. Three Data Collection Time Points Data Collection Point 1: First echo scan will be performed on the 5th Day of postnatal life (DoPL) together with the following data will be collected:
- Current weight in grams.
- Vital signs:
- Heart rate.
- Respiratory rate.
- Oxygen saturation.
- Temperature.
- BP including systolic, diastolic, and mean BP.
- Acquisition of the echo scan images.
- Ventilatory support:
- Mode of ventilation.
- Mean airway pressure (MAP) used.
- FiO2.
- Second echo scan will be performed on the 9th DoPL with the following will be collected:
- Infant's weight in grams.
- Vital signs:
- Heart rate.
- Respiratory rate.
- Oxygen saturation.
- Temperature.
- BP including systolic, diastolic, and mean BP.
- Acquisition of the echo scan images.
- Ventilatory support:
- Mode of ventilation.
- Mean airway pressure (MAP) used.
- FiO2.
- At 36 weeks of PMA or at discharge if discharged home before 36 weeks of PMA:
- Ventilatory support:
- Mode of ventilation.
- Mean airway pressure (MAP) used.
- FiO2.
- Outcomes. STATISTICS AND DATA ANALYSIS The distribution of all continuous variables will be visualised to check for normality and summarised using appropriate descriptive statistics. At 36 weeks, infants will be categorised into two groups: (i) moderate or severe BPD and (ii) mild or no BPD. In order to help identify potential candidate variables for inclusion in a predictive model the following analyses will be undertaken. Differences in clinical characteristics and echo scan parameters between the two groups of infants will be visualised using boxplots. The comparison between the two groups will be further assessed using t-tests for normally distributed continuous variables and Mann-Whitney U tests for non-normally distributed variables. Chi-squared tests will be used to compare categorical variables between groups. The association among clinical and echo parameters will also be explored through visualisation using scatterplots and Pearson's or Spearman's correlations as appropriate. Analyses will be considered exploratory in nature and as such no adjustment for multiple comparisons will be made - interpretation of these analyses will consider the estimates of the between group differences and their 95% confidence intervals. Comparative analyses of the changes between the two timepoints when the echo scans performed i.e., 5th and 9th day of postnatal life, will be conducted.
- Being tested
- Echo scans
- Keywords
- Right ventricular function, Bronchopulmonary Dysplasia, Prematurity, Neonates, Echocardiography
- Medical subject headings
- Bronchopulmonary Dysplasia, Ventricular Dysfunction, Right, Premature Birth
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Echo scansOther
Echo heart scan will be performed on the participating preterm infants on the 5th and 9th day of postnatal life.
| Study group | Role | What they receive |
|---|---|---|
| Preterm infants who are born before 32 weeks of gestation. | The study aims to recruit preterm infants who are born before 32 weeks of gestation. Receives: Other: Echo scans |
What is being measured
The primary outcome is the main question the study is designed to answer.
Effect of early Bronchopulmonary dysplasia on the heart right ventricle function.
Establishing sensitive and feasible echo parameters for detecting right ventricle dysfunction associated with early BPD pulmonary vascular changes.
Measured: 20 months
Secondary outcomes (3)
Suitability of eligibility criteria and sample characteristics.
Suitability of eligibility criteria and sample characteristics.
Measured: 20 months
Fidelity to the study procedures.
Fidelity to the study procedures such as recruitment, data collection including echo scans performance at the set time points.
Measured: 20 months
Acquiring relevant data
Recruitment, accrual, and retention rates.
Measured: 20 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Feb 2022
- Study start1 Jun 2022
- Primary completion5 May 2023
- Study completion5 May 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (25)Papers the sponsor has linked to this study.
- Other trials for Bronchopulmonary DysplasiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital Plymouth NHS Trust
- Sponsor type
- University, hospital or other
- Collaborators
- University of Plymouth
- Responsible party
- Sponsor
- Investigators
- WISAM S MUHSEN, MSc, Study chair, University of PlymouthJos Latour, PhD, Study director, University of PlymouthEirik Nestaas, PhD, Principal investigator, University of OsloJoanne Hosking, PhD, Principal investigator, University of Plymouth
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05235399
- Sponsor's protocol ID
- 22/NEO/636
- Other IDs
- 311906
- Acronym
- REPORT-BPD
- Status last verified
- Jan 2022
- First submitted
- 1 Feb 2022
- Last updated
- 1 Aug 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Appuhn SV, Siebert S, Myti D, Wrede C, Surate Solaligue DE, Perez-Bravo D, Brandenberger C, Schipke J, Morty RE, Grothausmann R, Muhlfeld C. Capillary Changes Precede Disordered Alveolarization in a Mouse Model of Bronchopulmonary Dysplasia. Am J Respir Cell Mol Biol. 2021 Jul;65(1):81-91. doi: 10.1165/rcmb.2021-0004OC.
PubMed 33784484Alvira CM. Aberrant Pulmonary Vascular Growth and Remodeling in Bronchopulmonary Dysplasia. Front Med (Lausanne). 2016 May 20;3:21. doi: 10.3389/fmed.2016.00021. eCollection 2016.
PubMed 27243014Ambalavanan N, Mourani P. Pulmonary hypertension in bronchopulmonary dysplasia. Birth Defects Res A Clin Mol Teratol. 2014 Mar;100(3):240-6. doi: 10.1002/bdra.23241. Epub 2014 Mar 10.
PubMed 24616323Breatnach CR, Levy PT, James AT, Franklin O, El-Khuffash A. Novel Echocardiography Methods in the Functional Assessment of the Newborn Heart. Neonatology. 2016;110(4):248-260. doi: 10.1159/000445779. Epub 2016 Jun 10.
PubMed 27287615Czernik C, Rhode S, Metze B, Schmalisch G, Buhrer C. Persistently elevated right ventricular index of myocardial performance in preterm infants with incipient bronchopulmonary dysplasia. PLoS One. 2012;7(6):e38352. doi: 10.1371/journal.pone.0038352. Epub 2012 Jun 1.
PubMed 22675548de Boode WP, Singh Y, Gupta S, Austin T, Bohlin K, Dempsey E, Groves A, Eriksen BH, van Laere D, Molnar Z, Nestaas E, Rogerson S, Schubert U, Tissot C, van der Lee R, van Overmeire B, El-Khuffash A. Recommendations for neonatologist performed echocardiography in Europe: Consensus Statement endorsed by European Society for Paediatric Research (ESPR) and European Society for Neonatology (ESN). Pediatr Res. 2016 Oct;80(4):465-71. doi: 10.1038/pr.2016.126. Epub 2016 Jun 8. No abstract available.
PubMed 27384404El-Khuffash A, Herbozo C, Jain A, Lapointe A, McNamara PJ. Targeted neonatal echocardiography (TnECHO) service in a Canadian neonatal intensive care unit: a 4-year experience. J Perinatol. 2013 Sep;33(9):687-90. doi: 10.1038/jp.2013.42. Epub 2013 Apr 25.
PubMed 23619373Erickson CT, Patel MD, Choudhry S, Bisselou KS, Sekarski T, Craft M, Li L, Khuffash AE, Hamvas A, Kutty S, Singh GK, Levy PT. Persistence of right ventricular dysfunction and altered morphometry in asymptomatic preterm Infants through one year of age: Cardiac phenotype of prematurity. Cardiol Young. 2019 Jul;29(7):945-953. doi: 10.1017/S1047951119001161. Epub 2019 Jul 9.
PubMed 31287038Higgins RD, Jobe AH, Koso-Thomas M, Bancalari E, Viscardi RM, Hartert TV, Ryan RM, Kallapur SG, Steinhorn RH, Konduri GG, Davis SD, Thebaud B, Clyman RI, Collaco JM, Martin CR, Woods JC, Finer NN, Raju TNK. Bronchopulmonary Dysplasia: Executive Summary of a Workshop. J Pediatr. 2018 Jun;197:300-308. doi: 10.1016/j.jpeds.2018.01.043. Epub 2018 Mar 16. No abstract available.
PubMed 29551318Ibrahim J, Bhandari V. The definition of bronchopulmonary dysplasia: an evolving dilemma. Pediatr Res. 2018 Nov;84(5):586-588. doi: 10.1038/s41390-018-0167-9. Epub 2018 Sep 4.
PubMed 30188504Islam JY, Keller RL, Aschner JL, Hartert TV, Moore PE. Understanding the Short- and Long-Term Respiratory Outcomes of Prematurity and Bronchopulmonary Dysplasia. Am J Respir Crit Care Med. 2015 Jul 15;192(2):134-56. doi: 10.1164/rccm.201412-2142PP.
PubMed 26038806Jensen EA, Dysart K, Gantz MG, McDonald S, Bamat NA, Keszler M, Kirpalani H, Laughon MM, Poindexter BB, Duncan AF, Yoder BA, Eichenwald EC, DeMauro SB. The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants. An Evidence-based Approach. Am J Respir Crit Care Med. 2019 Sep 15;200(6):751-759. doi: 10.1164/rccm.201812-2348OC.
PubMed 30995069Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001 Jun;163(7):1723-9. doi: 10.1164/ajrccm.163.7.2011060. No abstract available.
PubMed 11401896Khan U, Hjertaas JJ, Greve G, Matre K. Optimal Acquisition Settings for Speckle Tracking Echocardiography-Derived Strains in Infants: An In Vitro Study. Ultrasound Med Biol. 2016 Jul;42(7):1660-70. doi: 10.1016/j.ultrasmedbio.2016.02.015. Epub 2016 Apr 13.
PubMed 27085385Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70. doi: 10.1093/ehjci/jev014.
PubMed 25712077
Study at a glance
From the registry record, last updated by the sponsor on 1 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exploring Right vEntricular Function Applicability in a Prediction mOdel to Identify pReterm infanTs With Early BronchoPulmonary Dysplasia (REPORT - BPD Study): a Mixed Methods Observational Cohort Feasibility Study
- ClinicalTrials.gov ID
- NCT05235399
- Acronym / sponsor ID
- REPORT-BPD / 22/NEO/636
- Keywords
- Right ventricular function, Bronchopulmonary Dysplasia, Prematurity, Neonates, Echocardiography
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- University Hospital Plymouth NHS TrustUniversity, hospital or other
- Collaborators
- University of Plymouth
- Study start
- 1 Jun 2022 (actual)
- Primary completion
- 5 May 2023 (actual)
- Study completion
- 5 May 2023 (actual)
- First posted
- 11 Feb 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Short title REPORT-BPD feasibility study
Design A mixed methods observational cohort feasibility study
Study Setting Neonatal Intensive Care Unit at University Hospitals Plymouth NHS Trust
Aim To explore the feasibility of measuring the right ventricular function of the premature heart to develop a prediction model to identify early BronchoPulmonary Dysplasia in premature infants.
Objectives 1. To assess the feasibility and acceptability of the study procedures e.g., recruitment, echo scans performance, data collection, storage, and analysis.
- To identify the sensitive echo parameters in assessing the right ventricle function of the heart to be included in a prediction model to identify early BPD in premature infants.
Study Participants Preterm infants born <32 weeks of gestational age, their parents and healthcare professionals involved in the care of the study's preterm infants.
Sample size 40 preterm infants
Follow-up Each preterm infant will be followed up till they are 36 weeks of post menstrual age (PMA) or until discharge home whichever comes first.
Study Period 18 months
Outcome Measures
- Establishing sensitive and feasible echo parameters for detecting right ventricle dysfunction associated with early BPD pulmonary vascular changes.
- Suitability of eligibility criteria and sample characteristics.
- Fidelity to the study procedures such as recruitment, data collection including echo scans performance at the set time points.
- Recruitment, accrual, and retention rates.
Detailed description
RATIONALE The current research findings demonstrated a persistently elevated myocardial performance index of the right ventricle (RV) in the first two weeks of postnatal life (WoPL) in preterm infants with incipient BPD. The identification of the early myocardial dysfunction of RV that is associated with early pulmonary vascular disease (PVD) through echo scan examination in the first two WoPL can potentially serve as a marker for detecting preterm infants with an early BPD.
Data from 1,735 infants born between 23-30 weeks of gestational age (GA) showed that the proportion of preterm infants born < 31 weeks needing oxygen decreases from birth to the 7th day of postnatal life (DoPL). This is followed by a steep rise in the number of infants requiring oxygen in the same cohort at the start of the second week of postnatal life (WoPL). The number of preterm infants needing extra oxygen, peaks at the 14th DoPL. These studies indicate that the pathological pulmonary changes start as early as the first 10 DoPL. Furthermore, studies have identified the end of the first week of postnatal life (WoPL) and the beginning of the second WoPL as the time point when early respiratory problems start to surface. According to the vascular theory, the pathological processes affecting the pulmonary vascular bed are already happening before the appearance of the clinical signs associated with early BPD. The proposed study (REPORT-BPD) aims to capture the early burden exerted on the RV by early BPD and its associated pulmonary vascular changes through performing functional echo examinations at two time points, 5th and 9th day of postnatal life (DoPL) and utilising the findings to construct a prediction model.
To our knowledge, no study has used functional echo examinations to assess extra load or strain imposed by early BPD on the RV on the two time points (5th \& 9th DoPL) in the first 10 DoPL.
The cardiac muscle of the preterm infant's heart has premature function. The premature heart reduced contractility is secondary to several reasons such as less myofibrils per cross-sectional area together with immature internal organisation. In addition, there is a lower number of β-adrenergic receptors and underdeveloped sympathetic nervous network. Furthermore, the underdeveloped intrinsic myocardial function following preterm birth is the result of abnormal right ventricle performance with remodelling after birth that persists in the first year of life.
Current research supports the vascular theory as the main pathophysiology of BPD i.e., the pathological process of BPD starts in the pulmonary vascular bed prior to the involvement of the parenchyma of the lungs. So, when the early BPD respiratory insufficiency starts to manifest clinically on 7th day of postnatal life, the adverse haemodynamic changes are already ongoing. In addition, the immaturity of the right ventricle (RV) will render the RV more sensitive to the extra burden imposed by the negative haemodynamic effects of early BPD causing worsening of the RV dysfunction.
In summary, the rationale of the study is outlined nicely by a quote from Niccolo Michiavelli; an Italian diplomat, philosopher and historian, who lived during the renaissance (1469 - 1527):
"In the beginning of the malady it is easy to cure but difficult to detect, but in the course of time, not having been either detected or treated in the beginning, it becomes easy to detect but difficult to cure." To the best our knowledge, this is the first study that assesses the right ventricle dysfunction through two echo scans performed at two specified time points before and after the 7th day of postnatal life when early BPD respiratory insufficiency starts to be evident. Then, the data generated will be utilised to formulate a prediction model for early BPD. In other words, since it is very difficult to diagnose early BPD, this study will utilise highly specialised technologies in analysing the echo images and the data generated will be used to formulate a prediction model to identify BPD at its early stage. Additionally, the rationale behind incorporating qualitative work is because it is important to explore the experiences of parents and clinicians in participating in REPORT-BPD study to inform the design of a larger trial by addressing any gaps identified during this study.
OBJECTIVES
- To assess the feasibility and acceptability of the study procedures e.g., recruitment, echo scans performance, data collection, storage, and analysis.
- To identify the sensitive echo parameters in assessing the right ventricle function of the heart to be included in a prediction model to identify early BPD in premature infants.
STUDY DESIGN This is a longitudinal, observational, cohort and feasibility study. STUDY SETTING This study will be conducted at the regional tertiary neonatal intensive care unit (NICU) at University Hospitals Plymouth NHS Trust (UHP), Plymouth. The total NICU capacity is 40 neonatal admissions (6 intensive care cots, 6 high dependency care cots, 10 special care cots and 18 cots in transitional care ward).
SAMPLE AND RECRUITMENT
Sample size
The exploratory nature of this feasibility study dictated to set a realistic target of recruiting 40 preterm infants who are born before 32 weeks of gestation.
The regional tertiary NICU at the UHP admitted 89, 101 and 69 preterm infants who were born before 32 PMA in the years 2018, 2019 and 2020, respectively. Based on the careful examination of the data of the admissions in 2018; two thirds of these preterm infants met the inclusion criteria of the proposed study with one third of them i.e., eligible preterm infants developed moderate - severe BPD.
Therefore, the proposed feasibility study realistic sample size is 40 preterm infants over an 18-month recruitment period.
Participants
The participant whose data will be subjected to the trial analysis - both for the primary analysis and any applicable secondary analyses are:
- Infants survived till the gestational age when the diagnosis of no BPD or BPD with its severity can be established.
- Infants who died before the set gestational age (36 weeks PMA) with severe BPD is being the main cause of death. Participant identification The identification of eligible infants for the study will be carried out by the neonatal clinical team once a preterm infant is admitted to the regional tertiary NICU at UHP, either from the delivery suite in UHP or from another neonatal unit in the region for continuity of care. The neonatal clinical team will be consisted of the clinicians who are working in the neonatal unit such as, consultant neonatologists, trainee doctors, advanced neonatal nurse practitioners, neonatal staff nurses. While the neonatal research team is consisted of the clinicians such as, consultant neonatologists, trainee doctors and advanced nurse practitioners, who are good clinical practice (GCP) trained and registered in the study delegates' log. The neonatal clinical team will inform the neonatal research team of the potential recruits to instigate the recruitment process. Screening The screening process will occur on the possible two time points:
- Timepoint 1: If possible, antenatal screening will be carried out. The obstetric or midwifery team will inform the neonatal clinical team of the admitted women with preterm labour. This will be followed by screening for eligibility by the clinical neonatal team by reviewing the medical notes. Then the clinical neonatal team will inform the neonatal research team if the unborn infant is deemed a potential recruit so the initial conversation can happen antenatally.
- Timepoint 2: If screening is not possible at timepoint 1 parents of the suitable preterm infants will be approached in the second day after the birth of their infant. A screening log will be maintained. Consent All parents will be spoken to in person by the neonatal research team, who are also part of the neonatal clinical team, in the antenatal wards, in the delivery suite antenatally or in the neonatal unit postnatally. The neonatal research team members will clearly introduce themselves and state that this conversation will be about the parents and their preterm infants' participation in REPORT-BPD study. The talk will focus on providing a clear verbal explanation of the research project and why the parents and their preterm infants are invited to participate in this study, together with giving them a patient/parent information sheet (PIS) and informed consent form. The parents will also be given contact details for the chief investigator (CI) and the neonatal research team in case they wish to seek further information about the study. Informed and written consent to enter the study will be sought from each participant, in this case participants' parents. Signed parents' informed consent forms will be obtained prior to the participation in the study. If parents are interested in participating, a neonatal consultant, a senior trainee doctor or senior advanced nurse practitioner who is a member of the neonatal research team, will be able to dedicate some of their time to obtain consent at the second day after the birth of the potential recruit. All participants will be made aware that they are free to withdraw at any time from the study without giving reasons and without prejudicing further treatment. A delegation log will be maintained to ensure that the medical practitioners registered as a study delegate who are participating in the consenting process of this study, are duly authorised, completed a Good Clinical Practice (GCP) training, experienced clinicians and competent to participate according to the ethically approved protocol, principles of GCP and Declaration of Helsinki. DATA COLLECTION As per the standards of care echo scans are performed when one or more of the following clinical indications are present:
- Preterm infants who require mechanical ventilation or non-invasive respiratory support (CPAP ≥ 4 cm H2O, High Flow ≥ 4 L/min).
- Detection of a cardiac murmur in the first three days after birth.
- Assessment of patent ductus arteriosus (PDA).
- Preterm infants have central line in-situ, so echo is needed to assess line position. Three Data Collection Time Points Data Collection Point 1: First echo scan will be performed on the 5th Day of postnatal life (DoPL) together with the following data will be collected:
- Current weight in grams.
- Vital signs:
- Heart rate.
- Respiratory rate.
- Oxygen saturation.
- Temperature.
- BP including systolic, diastolic, and mean BP.
- Acquisition of the echo scan images.
- Ventilatory support:
- Mode of ventilation.
- Mean airway pressure (MAP) used.
- FiO2.
- Second echo scan will be performed on the 9th DoPL with the following will be collected:
- Infant's weight in grams.
- Vital signs:
- Heart rate.
- Respiratory rate.
- Oxygen saturation.
- Temperature.
- BP including systolic, diastolic, and mean BP.
- Acquisition of the echo scan images.
- Ventilatory support:
- Mode of ventilation.
- Mean airway pressure (MAP) used.
- FiO2.
- At 36 weeks of PMA or at discharge if discharged home before 36 weeks of PMA:
- Ventilatory support:
- Mode of ventilation.
- Mean airway pressure (MAP) used.
- FiO2.
- Outcomes. STATISTICS AND DATA ANALYSIS The distribution of all continuous variables will be visualised to check for normality and summarised using appropriate descriptive statistics. At 36 weeks, infants will be categorised into two groups: (i) moderate or severe BPD and (ii) mild or no BPD. In order to help identify potential candidate variables for inclusion in a predictive model the following analyses will be undertaken. Differences in clinical characteristics and echo scan parameters between the two groups of infants will be visualised using boxplots. The comparison between the two groups will be further assessed using t-tests for normally distributed continuous variables and Mann-Whitney U tests for non-normally distributed variables. Chi-squared tests will be used to compare categorical variables between groups. The association among clinical and echo parameters will also be explored through visualisation using scatterplots and Pearson's or Spearman's correlations as appropriate. Analyses will be considered exploratory in nature and as such no adjustment for multiple comparisons will be made - interpretation of these analyses will consider the estimates of the between group differences and their 95% confidence intervals. Comparative analyses of the changes between the two timepoints when the echo scans performed i.e., 5th and 9th day of postnatal life, will be conducted.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Preterm infants who are born before 32 weeks of gestation. | – | Other: Echo scansThe study aims to recruit preterm infants who are born before 32 weeks of gestation. |
Who may qualify
- Ages
- 2 to 2 days
- Sex
- All
- Age groups
- Child
- Study population
- The exploratory nature of this feasibility study dictated to set a realistic target of recruiting 40 preterm infants who are born before 32 weeks of gestation.
Key inclusion criteria (6 listed)
- Born at < 32 weeks gestational age.
- The echo scans are indicated as per the recommended neonatal practice:
Key exclusion criteria (6 listed)
- Preterm infants with major congenital anomalies, such as pulmonary hypoplasia or congenital heart disease (except PFO or PDA).
- Preterm infants with a poor prospect of survival.
- Preterm infants whose parents do not consent.
- Preterm infants who are still in need of blood pressure supporting medications, such as, (inotropes) when the study echo scans are due.
- Preterm infants need inhaled nitric oxide gas when the study echo scans are due.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Echo scansEcho heart scan will be performed on the participating preterm infants on the 5th and 9th day of postnatal life. | Other | Preterm infants who are born before 32 weeks of gestation. |
Primary outcome
Effect of early Bronchopulmonary dysplasia on the heart right ventricle function.
Time frame: 20 months
Establishing sensitive and feasible echo parameters for detecting right ventricle dysfunction associated with early BPD pulmonary vascular changes.
3 secondary outcomes
Suitability of eligibility criteria and sample characteristics.
Time frame: 20 months
Fidelity to the study procedures.
Time frame: 20 months
Acquiring relevant data
Time frame: 20 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Aug 2023.
- Background: PubMed 33784484Appuhn SV, Siebert S, Myti D, Wrede C, Surate Solaligue DE, Perez-Bravo D, Brandenberger C, Schipke J, Morty RE, Grothausmann R, Muhlfeld C. Capillary Changes Precede Disordered Alveolarization in a Mouse Model of Bronchopulmonary Dysplasia. Am J Respir Cell Mol Biol. 2021 Jul;65(1):81-91. doi: 10.1165/rcmb.2021-0004OC.
- Background: PubMed 27243014Alvira CM. Aberrant Pulmonary Vascular Growth and Remodeling in Bronchopulmonary Dysplasia. Front Med (Lausanne). 2016 May 20;3:21. doi: 10.3389/fmed.2016.00021. eCollection 2016.
- Background: PubMed 24616323Ambalavanan N, Mourani P. Pulmonary hypertension in bronchopulmonary dysplasia. Birth Defects Res A Clin Mol Teratol. 2014 Mar;100(3):240-6. doi: 10.1002/bdra.23241. Epub 2014 Mar 10.
- Background: PubMed 27287615Breatnach CR, Levy PT, James AT, Franklin O, El-Khuffash A. Novel Echocardiography Methods in the Functional Assessment of the Newborn Heart. Neonatology. 2016;110(4):248-260. doi: 10.1159/000445779. Epub 2016 Jun 10.
- Background: PubMed 22675548Czernik C, Rhode S, Metze B, Schmalisch G, Buhrer C. Persistently elevated right ventricular index of myocardial performance in preterm infants with incipient bronchopulmonary dysplasia. PLoS One. 2012;7(6):e38352. doi: 10.1371/journal.pone.0038352. Epub 2012 Jun 1.
- Background: PubMed 27384404de Boode WP, Singh Y, Gupta S, Austin T, Bohlin K, Dempsey E, Groves A, Eriksen BH, van Laere D, Molnar Z, Nestaas E, Rogerson S, Schubert U, Tissot C, van der Lee R, van Overmeire B, El-Khuffash A. Recommendations for neonatologist performed echocardiography in Europe: Consensus Statement endorsed by European Society for Paediatric Research (ESPR) and European Society for Neonatology (ESN). Pediatr Res. 2016 Oct;80(4):465-71. doi: 10.1038/pr.2016.126. Epub 2016 Jun 8. No abstract available.
- Background: PubMed 23619373El-Khuffash A, Herbozo C, Jain A, Lapointe A, McNamara PJ. Targeted neonatal echocardiography (TnECHO) service in a Canadian neonatal intensive care unit: a 4-year experience. J Perinatol. 2013 Sep;33(9):687-90. doi: 10.1038/jp.2013.42. Epub 2013 Apr 25.
- Background: PubMed 31287038Erickson CT, Patel MD, Choudhry S, Bisselou KS, Sekarski T, Craft M, Li L, Khuffash AE, Hamvas A, Kutty S, Singh GK, Levy PT. Persistence of right ventricular dysfunction and altered morphometry in asymptomatic preterm Infants through one year of age: Cardiac phenotype of prematurity. Cardiol Young. 2019 Jul;29(7):945-953. doi: 10.1017/S1047951119001161. Epub 2019 Jul 9.
- Background: PubMed 29551318Higgins RD, Jobe AH, Koso-Thomas M, Bancalari E, Viscardi RM, Hartert TV, Ryan RM, Kallapur SG, Steinhorn RH, Konduri GG, Davis SD, Thebaud B, Clyman RI, Collaco JM, Martin CR, Woods JC, Finer NN, Raju TNK. Bronchopulmonary Dysplasia: Executive Summary of a Workshop. J Pediatr. 2018 Jun;197:300-308. doi: 10.1016/j.jpeds.2018.01.043. Epub 2018 Mar 16. No abstract available.
- Background: PubMed 30188504Ibrahim J, Bhandari V. The definition of bronchopulmonary dysplasia: an evolving dilemma. Pediatr Res. 2018 Nov;84(5):586-588. doi: 10.1038/s41390-018-0167-9. Epub 2018 Sep 4.
- Background: PubMed 26038806Islam JY, Keller RL, Aschner JL, Hartert TV, Moore PE. Understanding the Short- and Long-Term Respiratory Outcomes of Prematurity and Bronchopulmonary Dysplasia. Am J Respir Crit Care Med. 2015 Jul 15;192(2):134-56. doi: 10.1164/rccm.201412-2142PP.
- Background: PubMed 30995069Jensen EA, Dysart K, Gantz MG, McDonald S, Bamat NA, Keszler M, Kirpalani H, Laughon MM, Poindexter BB, Duncan AF, Yoder BA, Eichenwald EC, DeMauro SB. The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants. An Evidence-based Approach. Am J Respir Crit Care Med. 2019 Sep 15;200(6):751-759. doi: 10.1164/rccm.201812-2348OC.
- Individual participant dataSharing planned: No
Related trials for Bronchopulmonary Dysplasia
RecruitingPhase 4
Impact of Higher Zinc Supplementation on Neonatal Weight Velocity
Extreme Prematurity,Extremely Low Birthweight, BPD - Bronchopulmonary Dysplasia
Not yet recruiting
Strap To Reduce Apnea in Preterm Infants: A Randomized Crossover Trial
Apnea of Prematurity, Intermittent Hypoxemia
Recruiting
Ventilator Pressure and Optimization of Compliance and Hemodynamics
Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Recruiting
Restricted Versus Liberal Fluid Intake for Prevention of Bronchopulmonary Dysplasia
Bronchopulmonary Dysplasia
RecruitingObservational study
The Correlation Between Red Cell Transfusion and Complications of Prematurity
Retinopathy of Prematurity (ROP), Bronchopulmonary Dysplasia (BPD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
WISAM S MUHSEN, MSc study chair
University of Plymouth
Jos Latour, PhD study director
University of Plymouth
Eirik Nestaas, PhD principal investigator
University of Oslo
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Bronchopulmonary Dysplasia and Right Ventricular Dysfunction, run by University Hospital Plymouth NHS Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Effect of early Bronchopulmonary dysplasia on the heart right ventricle function. (time frame: 20 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05235399, which also lists 25 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Aug 2023.